Alkaloids from Psychotria Target Sirtuins: In Silico and In Vitro Interaction Studies
Abstract Epigenetic enzymes such as histone deacetylases play a crucial role in the development of ageing-related diseases. Among the 18 histone deacetylase isoforms found in humans, class III histone deacetylases, also known as sirtuins, seem to be promising targets for treating neurodegenerative c...
Saved in:
Published in | Planta medica Vol. 81; no. 6; pp. 517 - 524 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Stuttgart · New York
Georg Thieme Verlag KG
01.04.2015
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Abstract
Epigenetic enzymes such as histone deacetylases play a crucial role in the development of ageing-related diseases. Among the 18 histone deacetylase isoforms found in humans, class III histone deacetylases, also known as sirtuins, seem to be promising targets for treating neurodegenerative conditions. Recently,
Psychotria
alkaloids, mainly monoterpene indoles, have been reported for their inhibitory properties against central nervous system cholinesterase and monoamine oxidase proteins. Given the multifunctional profile of these alkaloids in the central nervous system, and the fact that the indole scaffold has been previously associated with sirtuin inhibition, we hypothesized that these indole derivatives could also interact with sirtuins. In the present study, alkaloids previously isolated from
Psychotria
spp. were evaluated for their potential interaction with human sirtuin 1 and sirtuin 2 by molecular docking and molecular dynamics simulation approaches. The
in silico
results allowed for the selection of five potentially active compounds, namely, prunifoleine, 14-oxoprunifoleine,
E
-vallesiachotamine,
Z
-vallesiachotamine, and
vallesiachotamine lactone. The sirtuin inhibition of these compounds was confirmed
in vitro
in a dose-response manner, with preliminary information on their pharmacokinetics properties. |
---|---|
ISSN: | 0032-0943 1439-0221 |
DOI: | 10.1055/s-0034-1383261 |